High frequency of low-count monoclonal B-cell lymphocytosis in hospitalized COVID-19 patients

[EN]Low-count monoclonal B-cell lymphocytosis (MBLlo) is associated with clinical and biological features typical of an underlying immunodeficiency, which may be a risk factor for developing more severe infections. Here we studied the frequency of MBLlo among COVID-19 patients and its potential impa...

Descripción completa

Detalles Bibliográficos
Autores: Oliva Ariza, Guillermo, Fuentes Herrero, Blanca, Carbonell Muñoz, Cristina, Lécrevisse, Quentin André, Pérez Pons, Alba, Torres Valle, Alba, Pozo, Julio, Martín Oterino, José Ángel, González López, Oscar, López Bernús, Amparo Agustina, Bernal Ribes, Marta, Belhassen García, Moncef, Pérez Escurza, Oihane, Pérez Andrés, Martín, Vazquez, Lourdes, Hernández-Pérez, Guillermo, García Palomo, Francisco Javier, Leoz, Pilar, Costa Alba, Pilar, Pérez Losada, Elena, Yeguas, Ana, Santos Sánchez, Miryan, García Blázquez, Marta, Morán Plata, Francisco Javier, Pinto Damasceno, Daniela, Botafogo Goncalves, Vitor, Muñoz García, Noemi, Fluxa, Rafael, Contreras Sanfeliciano, Teresa, Almeida Parra, Julia María, Marcos Martín, Miguel, Orfao de Matos Correia e Vale, José Alberto
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Universidad de Salamanca (USAL)
Repositorio:GREDOS. Repositorio Institucional de la Universidad de Salamanca
OAI Identifier:oai:gredos.usal.es:10366/168684
Acceso en línea:http://hdl.handle.net/10366/168684
Access Level:acceso abierto
Palabra clave:Monoclonal B-cell Lymphocytosis
MBL
COVID 19
B-Lymphocytes
Risk Factors
Immunoglobulins
linfocitos B
inmunoglobulinas
factores de riesgo
Descripción
Sumario:[EN]Low-count monoclonal B-cell lymphocytosis (MBLlo) is associated with clinical and biological features typical of an underlying immunodeficiency, which may be a risk factor for developing more severe infections. Here we studied the frequency of MBLlo among COVID-19 patients and its potential impact on disease severity. The presence of MBLlo was investigated in blood of 249 COVID-19 patients vs. a pre-COVID-19 cohort of 728 individuas, using high-sensitivity flow cytometry; plasma levels of anti-SARS-CoV-2 antibodies were measured by ELISA. Overall, MBLlo was detected in 29% of COVID-19 patients (vs. 14% in the general pre-COVID-19 population; p<0.0001), particularly among hospitalized patients (40%; p<0.0001), with a tendency toward a predominance in men. MBLlo patients showed features of more severe COVID-19 than non-MBL cases, including more frequent (85% vs. 60%; p=0.0001) and longer (14 vs. 10 days; p=0.03) hospitalization, higher oxygen therapy (70% vs. 39%; p<0.0001) and need for intensive care (15% vs. 6%; p=0.02). Except for lower B-cell counts at recovery in MBLlo cases (p=0.04), similarly altered immune-cell profiles were observed in patients with and without MBLlo. In contrast, MBLlo patients showed a significantly higher percentage of detectable anti-SARS-CoV-2 IgM/IgG/IgA antibodies in plasma, associated with higher IgA SARS-CoV-2 specific antibody levels during acute infection. In conclusion, MBLlo is significantly more prevalent in COVID-19 patients vs. the general population, and it is associated with more severe COVID-19, further supporting the existence of a pre-established immunodeficiency already at early MBL stages.

Similares en LA Referencia